A pharmaceutical giant joins forces
with a not-for-profit partner to drive
down the cost of malaria treatment.
TE FOR ONEWORLD HEALTH, SAN FRANCISCO, CALIFORNIA, USA
PHOTO BY MATTHIEU DELUC
Sometimes the prescription for global medical issues requires a double dose of assistance. In 2007, the Institute for One World Health launched a project aimed at developing a more affordable malaria treatment for use in the
The group knew it couldn’t go it alone, but
it also knew not just any partner would do.
As with all of its projects, One World Health
solicited proposals and then launched into a
thorough vetting process.
“The more time spent planning the project
and making sure the two partners are aligned,
the better,” says Kay Monroe, director of project
management for OneWorld Health’s malaria
project. “It saves a lot of time and money on
the back end because everyone is focused on
the same goals.”
After months of evaluation and face-to-face meetings with several potential partners,
OneWorld Health chose Sanofi-Aventis in
And while it’s certainly noble for the
research and pharmaceutical company to sign
on to the project, it’s also a core part of its
Sanofi-Aventis regularly teams up with not-for-profits and government agencies on projects
to address medical issues around the world,
says Henri Farret, industrial affairs/chemistry
projects director at the company.
“Sanofi-Aventis has a department called
Access to Medicines, which has the objective of
providing poor patients with low-cost medicines
for ‘killing diseases,’ like tuberculosis, malaria
and leishmaniasis,” Mr. Farret says.
The team has a core focus, zeroing in on
seven medical issues where the Sanofi-Aventis product portfolio and know-how
can make a difference, explains Philippe